The global pharmaceutical industry faces a pressing need for new untapped sources of pre-clinical and clinical stage compounds for the drug development process.  HUYA developed an innovative approach – the HUYA Integrated Co-development Model – for partnering with Chinese research institutions and pharmaceutical companies to bring promising novel compounds into the Western development process and biopharma market. 

HUYA scouts for and targets drug compounds that have already demonstrated promising results within China’s SFDA (State Food and Drug Administration, China) testing program and provides a bridge to Western pharmaceutical partners.  The data gathered from the SFDA testing provides invaluable guidance regarding the best methods and procedures for FDA and EMEA submissions in the West.  Because the compounds have been rigorously evaluated and validated in China, Western partners benefit from streamlined development, lower costs, and greatly reduced risk.  

HUYA’s Strategic Advantages

·      A team of world-class managers and advisors (both in the U.S. and China) with significant industry and cross-cultural experience.

·      A growing reputation as the first contact point for Chinese biopharmaceutical companies, technology centers and universities with pharmaceuticals targeted at Western markets.

·      The ability to perform extensive due diligence and secure exclusive worldwide rights (outside of China) to the most promising development stage drugs available from China.

·      An innovative co-development model that leverages the capabilities of Chinese partners during the critical early stages of development and strategically partners to accelerate the development of drugs to Western standards.

·      Investment in the success of its Chinese partners through capital, data sharing, and knowledge.

·      Strategically placed offices in Shanghai (HUYA headquarters) and Beijing with satellite offices in Hangzhou and Shenzhen to leverage the major hubs of biotech activity in China.